Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

Core Insights - The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Caribou Biosciences' CB-011 for relapsed or refractory multiple myeloma (r/r MM), recognizing the significant unmet medical need and promising clinical data from the ongoing CaMMouflage phase 1 trial [1][3] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that has shown a 92% overall response rate (ORR) and a 75% complete response (CR) rate in a cohort of BCMA-naïve patients [2][4] - The ongoing dose expansion phase of the CaMMouflage trial is expected to provide additional data in 2026, with a focus on both BCMA-naïve and BCMA-exposed patient cohorts [1][5] Company Overview - Caribou Biosciences, Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company focused on developing transformative therapies for serious diseases, particularly hematologic malignancies [7] - The company is advancing CB-011 and vispacabtagene regedleucel (vispa-cel) as off-the-shelf CAR-T cell therapies aimed at improving patient access and treatment speed [7] Clinical Trial Details - The CaMMouflage phase 1 clinical trial is a multicenter, open-label study evaluating CB-011 in adults with r/r MM who have undergone three or more prior lines of therapy [5][6] - The trial has treated 48 patients in the dose escalation portion, with a recommended dose for expansion set at 450x10 CAR-T cells [2][6] - Safety data indicate a manageable profile for CB-011, with no cases of severe adverse events such as graft-versus-host disease reported [2][3]